MedTrace Logo

Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

NCT05760703 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-12-19

No results posted yet for this study

Summary

This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy(Long-term follow-up).

Conditions

Interventions

DRUG

STSG-0002 Injection

Intravenous infusion

Sponsors & Collaborators

  • Beijing Sanuo Jiayi Biotechnology Co. LTD

    collaborator UNKNOWN

  • Staidson (Beijing) Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Guiqiang Wang · Peking University First Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2023-12-11
Completion
2023-12-11

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05760703 on ClinicalTrials.gov